Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
- Written by The Chronicle
BEIJING, CHINA - Media OutReach - 6 June 2022 - Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.